All companies
Visit website
Speranza Therapeutics
OperatingSperanza Therapeutics, Inc.
Technology · Founded 2019
Develops, distributes and clinically supports medical devices and generic drugs that treat disease
Post-money valuation ⓘ
$76.8M
As of Sep 2022 · from Speranza Therapeutics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$56,409
Across 1 round since 2022
Latest share price
$6.89
Speranza Therapeutics Common Stock 1 offering price
Financials
FY2019–FY2021 · from SEC filings · hover any figure for its source$790K
−$1.6M
2019
$790K
$1.6M
2020
$126K
$2.0M
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
Income statement
Revenue
$789,775
$789,775
$126,310
Cost of goods sold
$518,475
$518,475
$187,705
Gross margin
34%
34%
-49%
Net income
-$1,594,376
$1,594,376
$1,969,611
Taxes paid
$12,177
$12,177
$0
Balance sheet
Cash
$32,002
$32,002
$34,245
Accounts receivable
$129,134
$129,134
$7,700
Total assets
$1,532,092
$1,532,092
$1,204,058
Short-term debt
$869,977
$869,977
$2,116,970
Long-term debt
$0
$0
$0
Total liabilities
$869,977
$869,977
$2,116,970
Other
Headcount
—
8
8
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$76.8M
post-money
Speranza Therapeutics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $56.4K / $1.1MInvestors 2Post-money $76.8M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 5 annual reports (FY2021–FY2025)
2 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001915964Share price $6.89
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.